Literature DB >> 23998333

Maternal-fetal HLA sharing and preeclampsia: variation in effects by seminal fluid exposure in a case-control study of nulliparous women in Iowa.

Elizabeth W Triche1, Karisa K Harland2, Elizabeth H Field3, Linda M Rubenstein4, Audrey F Saftlas4.   

Abstract

Whereas histocompatibility is critical for transplantation, HLA histoincompatibility is associated with successful pregnancy. Literature on HLA sharing and preeclampsia has been inconsistent; most studies focused on maternal-paternal rather than maternal-fetal sharing. This study examines whether maternal-fetal histocompatibility is associated with preeclampsia, and whether effects vary by semen exposure history. This case-control study of nulliparous women was designed to examine associations among HLA sharing, semen exposure, and preeclampsia. 258 preeclampsia cases and 182 normotensive controls met the eligibility criteria. HLA typing for mother and baby was performed for HLA-A, -B, -C, -DRB1, and -DQB1. We further restricted our study sample to 224 mother-baby pairs who had complete HLA typing for all five genes. Seminal fluid exposure indexes incorporated information on type of practice, frequency, contraceptive use (for vaginal exposure) and ingestion practices (for oral exposure). Multivariate models were adjusted for BMI and education. HLA-A matching, Class I matching, and combined Class I and II matching were associated with increased odds of preeclampsia. Among women with low semen exposure, effects of Class I matching were amplified (HLA-A matching, OR=6.27, 95%CI=1.04, 37.97; Class I matching, OR=4.49 per one-match increase, 95%CI=1.89, 14.50). With moderate to high semen exposure, Class II matching effects predominated (HLA-DQB1, OR=3.22, 95%CI=1.04, 9.99; Class II, OR=1.76 per one-match increase, 95%CI=1.05, 2.98; and total matches, OR=1.45 per one-match increase, 95%CI=1.02, 2.06). We found consistent evidence that maternal-fetal HLA sharing was associated with preeclampsia in a pattern influenced by prior vaginal exposure to paternal seminal fluid.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  HLA sharing; Immunology; Maternal–fetal histocompatibility; Preeclampsia; Seminal fluid

Mesh:

Substances:

Year:  2013        PMID: 23998333      PMCID: PMC4060772          DOI: 10.1016/j.jri.2013.06.004

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  47 in total

Review 1.  Immunology of pre-eclampsia.

Authors:  Christopher W G Redman; Ian L Sargent
Journal:  Am J Reprod Immunol       Date:  2010-03-23       Impact factor: 3.886

2.  Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2.

Authors:  Susan E Hiby; Richard Apps; Andrew M Sharkey; Lydia E Farrell; Lucy Gardner; Arend Mulder; Frans H Claas; James J Walker; Christopher W Redman; Christopher C Redman; Linda Morgan; Clare Tower; Lesley Regan; Gudrun E Moore; Mary Carrington; Ashley Moffett
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

Review 3.  Pre-eclampsia: Is the immune maladaptation hypothesis still standing? An epidemiological update.

Authors:  Gus Dekker; Pierre-Yves Robillard
Journal:  J Reprod Immunol       Date:  2007-05-09       Impact factor: 4.054

4.  Abortion and its effect on risk of preeclampsia and transient hypertension.

Authors:  J L Eras; A F Saftlas; E Triche; C D Hsu; H A Risch; M B Bracken
Journal:  Epidemiology       Date:  2000-01       Impact factor: 4.822

5.  An epidemiologic study of contraception and preeclampsia.

Authors:  H S Klonoff-Cohen; D A Savitz; R C Cefalo; M F McCann
Journal:  JAMA       Date:  1989-12-08       Impact factor: 56.272

6.  Increased HLA-DR homozygosity associated with pre-eclampsia.

Authors:  I de Luca Brunori; L Battini; M Simonelli; F Clemente; E Brunori; M L Mariotti; A R Genazzani
Journal:  Hum Reprod       Date:  2000-08       Impact factor: 6.918

7.  Abortion, changed paternity, and risk of preeclampsia in nulliparous women.

Authors:  Audrey F Saftlas; Richard J Levine; Mark A Klebanoff; Karen L Martz; Marian G Ewell; Cynthia D Morris; Baha M Sibai
Journal:  Am J Epidemiol       Date:  2003-06-15       Impact factor: 4.897

8.  HLA antigens-antibodies system and its association with severe toxemia of pregnancy.

Authors:  S Fujisawa
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1985-01

9.  Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004.

Authors:  Anne B Wallis; Audrey F Saftlas; Jason Hsia; Hani K Atrash
Journal:  Am J Hypertens       Date:  2008-03-13       Impact factor: 2.689

10.  Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success.

Authors:  Susan E Hiby; James J Walker; Kevin M O'shaughnessy; Christopher W G Redman; Mary Carrington; John Trowsdale; Ashley Moffett
Journal:  J Exp Med       Date:  2004-10-11       Impact factor: 14.307

View more
  15 in total

1.  Physical Activity During Pregnancy and Subsequent Risk of Preeclampsia and Gestational Hypertension: A Case Control Study.

Authors:  Cassandra N Spracklen; Kelli K Ryckman; Elizabeth W Triche; Audrey F Saftlas
Journal:  Matern Child Health J       Date:  2016-06

2.  Genetic Risk Score for Essential Hypertension and Risk of Preeclampsia.

Authors:  Caitlin J Smith; Audrey F Saftlas; Cassandra N Spracklen; Elizabeth W Triche; Andrew Bjonnes; Brendan Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman
Journal:  Am J Hypertens       Date:  2015-05-23       Impact factor: 2.689

Review 3.  Regulatory T cells in embryo implantation and the immune response to pregnancy.

Authors:  Sarah A Robertson; Alison S Care; Lachlan M Moldenhauer
Journal:  J Clin Invest       Date:  2018-10-01       Impact factor: 14.808

4.  Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia.

Authors:  Cassandra N Spracklen; Audrey F Saftlas; Elizabeth W Triche; Andrew Bjonnes; Brendan Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman
Journal:  Am J Hypertens       Date:  2014-12-17       Impact factor: 2.689

5.  Risk of recurrent preterm birth among women according to change in partner.

Authors:  Rebecca J Baer; Juan Yang; Christina D Chambers; Kelli K Ryckman; Audrey F Saftlas; Vincenzo Berghella; Chris Dunkel Schetter; Gary M Shaw; David K Stevenson; Laura L Jelliffe-Pawlowski
Journal:  J Perinat Med       Date:  2017-01-01       Impact factor: 1.901

6.  Genetic predisposition to elevated levels of C-reactive protein is associated with a decreased risk for preeclampsia.

Authors:  Cassandra N Spracklen; Caitlin J Smith; Audrey F Saftlas; Elizabeth W Triche; Andrew Bjonnes; Brendan J Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman
Journal:  Hypertens Pregnancy       Date:  2016-09-22       Impact factor: 2.108

7.  Maternal and fetal human leukocyte antigen class Ia and II alleles in severe preeclampsia and eclampsia.

Authors:  J Emmery; R Hachmon; C W Pyo; W C Nelson; D E Geraghty; A M N Andersen; M Melbye; T V F Hviid
Journal:  Genes Immun       Date:  2016-04-28       Impact factor: 2.676

8.  Effects of smoking and preeclampsia on birth weight for gestational age.

Authors:  Cassandra N Spracklen; Kelli K Ryckman; Karisa Harland; Audrey F Saftlas
Journal:  J Matern Fetal Neonatal Med       Date:  2014-06-26

9.  Maternal-Fetal HLA Compatibility in Uncomplicated and Preeclamptic Naturally Conceived Pregnancies.

Authors:  Liseanne J van 't Hof; Naomi Schotvanger; Geert W Haasnoot; Carin van der Keur; Dave L Roelen; Lisa E E L O Lashley; Frans H J Claas; Michael Eikmans; Marie-Louise P van der Hoorn
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

10.  Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.

Authors:  Louise C Kenny; Douglas B Kell
Journal:  Front Med (Lausanne)       Date:  2018-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.